Literature DB >> 30237756

The Molecular Basis of Metastatic Colorectal Cancer.

Sarah F Andres1, Kathy N Williams1, Anil K Rustgi1.   

Abstract

PURPOSE OF REVIEW: Metastatic colorectal cancer (CRC) is a vexing clinical problem. In contrast to early stage disease, once CRC metastasizes to other organs, long-term survival is compromised. We seek to review the molecular pathogenesis, animal models, and functional genomics for an enhanced understanding of how CRC metastasizes and how this can be exploited therapeutically. RECENT
FINDINGS: Mouse models may recapitulate certain aspects of metastatic human CRC and allow for studies to identify regulators of metastasis. Modulation of transcription factors, onco-proteins, or tumor suppressors have been identified to activate known metastatic pathways. CD44 variants, microRNAs and RNA binding proteins are emerging as metastatic modulators.
SUMMARY: CRC metastasis is a multi-faceted and heterogeneous disease. Despite common pathways contributing to metastatic development, there are numerous variables that modulate metastatic signals in subsets of patients. It is paramount that studies continue to investigate metastatic drivers, enhancers and inhibitors in CRC to develop therapeutic targets and improve disease outcomes.

Entities:  

Keywords:  CD44; HGF; KRAS; WNT TGFβ; signaling pathways

Year:  2018        PMID: 30237756      PMCID: PMC6141197          DOI: 10.1007/s11888-018-0403-z

Source DB:  PubMed          Journal:  Curr Colorectal Cancer Rep        ISSN: 1556-3790


  92 in total

Review 1.  The Met pathway: master switch and drug target in cancer progression.

Authors:  Massimiliano Mazzone; Paolo M Comoglio
Journal:  FASEB J       Date:  2006-08       Impact factor: 5.191

2.  IL13 Receptor α2 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis.

Authors:  Rubén A Bartolomé; Irene García-Palmero; Sofía Torres; María López-Lucendo; Irina V Balyasnikova; J Ignacio Casal
Journal:  Cancer Res       Date:  2015-04-20       Impact factor: 12.701

3.  Mutant KRAS promotes hyperplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool.

Authors:  Ying Feng; Guido T Bommer; Jenny Zhao; Maranne Green; Evan Sands; Yali Zhai; Kelly Brown; Aaron Burberry; Kathleen R Cho; Eric R Fearon
Journal:  Gastroenterology       Date:  2011-05-18       Impact factor: 22.682

Review 4.  Wnt/beta-catenin signaling in cancer stemness and malignant behavior.

Authors:  Riccardo Fodde; Thomas Brabletz
Journal:  Curr Opin Cell Biol       Date:  2007-02-16       Impact factor: 8.382

5.  Enhanced CLIP Uncovers IMP Protein-RNA Targets in Human Pluripotent Stem Cells Important for Cell Adhesion and Survival.

Authors:  Anne E Conway; Eric L Van Nostrand; Gabriel A Pratt; Stefan Aigner; Melissa L Wilbert; Balaji Sundararaman; Peter Freese; Nicole J Lambert; Shashank Sathe; Tiffany Y Liang; Anthony Essex; Severine Landais; Christopher B Burge; D Leanne Jones; Gene W Yeo
Journal:  Cell Rep       Date:  2016-04-07       Impact factor: 9.423

6.  Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions.

Authors:  Felix H Brembeck; Thomas Schwarz-Romond; Jeroen Bakkers; Sabine Wilhelm; Matthias Hammerschmidt; Walter Birchmeier
Journal:  Genes Dev       Date:  2004-09-01       Impact factor: 11.361

7.  Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis.

Authors:  Yoshiro Itatani; Kenji Kawada; Teruaki Fujishita; Fumihiko Kakizaki; Hideyo Hirai; Takuya Matsumoto; Masayoshi Iwamoto; Susumu Inamoto; Etsuro Hatano; Suguru Hasegawa; Taira Maekawa; Shinji Uemoto; Yoshiharu Sakai; Makoto Mark Taketo
Journal:  Gastroenterology       Date:  2013-07-25       Impact factor: 22.682

8.  BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis.

Authors:  Naoya Sakamoto; Ying Feng; Carmine Stolfi; Yuki Kurosu; Maranne Green; Jeffry Lin; Megan E Green; Kazuhiro Sentani; Wataru Yasui; Martin McMahon; Karin M Hardiman; Jason R Spence; Nobukatsu Horita; Joel K Greenson; Rork Kuick; Kathleen R Cho; Eric R Fearon
Journal:  Elife       Date:  2017-01-10       Impact factor: 8.140

9.  EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients.

Authors:  Sriram Srivatsa; Mariel C Paul; Claudia Cardone; Martin Holcmann; Nicole Amberg; Paulina Pathria; Michaela A Diamanti; Markus Linder; Gerald Timelthaler; Hans P Dienes; Lukas Kenner; Fritz Wrba; Gerald W Prager; Stefan Rose-John; Robert Eferl; Giuseppina Liguori; Gerardo Botti; Erika Martinelli; Florian R Greten; Fortunato Ciardiello; Maria Sibilia
Journal:  Gastroenterology       Date:  2017-04-09       Impact factor: 22.682

10.  Oncogenic Kras drives invasion and maintains metastases in colorectal cancer.

Authors:  Adam T Boutin; Wen-Ting Liao; Melody Wang; Soyoon Sarah Hwang; Tatiana V Karpinets; Hannah Cheung; Gerald C Chu; Shan Jiang; Jian Hu; Kyle Chang; Eduardo Vilar; Xingzhi Song; Jianhua Zhang; Scott Kopetz; Andrew Futreal; Y Alan Wang; Lawrence N Kwong; Ronald A DePinho
Journal:  Genes Dev       Date:  2017-03-13       Impact factor: 11.361

View more
  3 in total

1.  IMP1 3' UTR shortening enhances metastatic burden in colorectal cancer.

Authors:  Sarah F Andres; Kathy N Williams; Jacqueline B Plesset; Jeffrey J Headd; Rei Mizuno; Priya Chatterji; Ashley A Lento; Andres J Klein-Szanto; Rosemarie Mick; Kathryn E Hamilton; Anil K Rustgi
Journal:  Carcinogenesis       Date:  2019-06-10       Impact factor: 4.944

2.  Oxytocin Inhibition of Metastatic Colorectal Cancer by Suppressing the Expression of Fibroblast Activation Protein-α.

Authors:  Mingxing Ma; Li Li; He Chen; Yong Feng
Journal:  Front Neurosci       Date:  2019-12-13       Impact factor: 4.677

3.  Molecular features and gene expression signature of metastatic colorectal cancer (Review).

Authors:  Martina Poturnajova; Tatiana Furielova; Sona Balintova; Silvia Schmidtova; Lucia Kucerova; Miroslava Matuskova
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.